CivicaRx wants to change drug costs by working with pharma

Amy Baxter | | Health Exec | Policy & Regulations

CivicaRx, the not-for-profit entity created last year by a group of health systems and hospitals, is planning to achieve its goals of lowering drug prices and addressing shortages in hospitals by working directly with pharmaceutical companies and buying drugs, Bloomberg reported.

When the entity first came to fruition, its stated goal was to manufacture its own drugs after hospitals faced shortages for many common drugs. For now, it seems CivicaRx will serve as a marketplace entity, buying drugs from pharmaceutical companies and acting as a go-between for hospitals, according to Bloomberg.

“With that critical need, almost a national drug-shortage crisis, we had to discover what was the fastest way to get products into the market,” CivicaRx CEO Martin VanTrieste told Bloomberg.

See the full story below:

Nonprofit Trying to Upend Drug Costs Will Work With Pharma, Not Against It

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

FDA set to ban certain over-the-counter cold medications
FDA commissioner urges clinicians to join fight against medical misinformation
Looming fear of more IV shortages as Hurricane Rafael gains strength
Walgreens settles class-action fraud lawsuit for $100M
Boston Medical Center installs solar panels to pay patients’ electric bills
4 points crucial to the nimble regulation of GenAI

Around the web

Cardiovascular Business
FDA commissioner urges clinicians to join fight against medical misinformation

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."
 

AI in Healthcare
4 points crucial to the nimble regulation of GenAI

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup